Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 38548752)

  • 21. Constitutive asymmetric dimerization drives oncogenic activation of epidermal growth factor receptor carboxyl-terminal deletion mutants.
    Park AK; Francis JM; Park WY; Park JO; Cho J
    Oncotarget; 2015 Apr; 6(11):8839-50. PubMed ID: 25826094
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Dacomitinib overcomes afatinib-refractory carcinomatous meningitis in a lung cancer patient harbouring EGFR Ex.19 deletion and G724S mutation; a case report.
    Kunimasa K; Sugimoto N; Tamiya M; Inoue T; Kawamura T; Kanzaki R; Okami J; Nishino K
    Invest New Drugs; 2022 Oct; 40(5):1137-1140. PubMed ID: 35657573
    [TBL] [Abstract][Full Text] [Related]  

  • 23. APOBEC mutagenesis, kataegis, chromothripsis in EGFR-mutant osimertinib-resistant lung adenocarcinomas.
    Selenica P; Marra A; Choudhury NJ; Gazzo A; Falcon CJ; Patel J; Pei X; Zhu Y; Ng CKY; Curry M; Heller G; Zhang YK; Berger MF; Ladanyi M; Rudin CM; Chandarlapaty S; Lovly CM; Reis-Filho JS; Yu HA
    Ann Oncol; 2022 Dec; 33(12):1284-1295. PubMed ID: 36089134
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A real-world study of dacomitinib in later-line settings for advanced non-small cell lung cancer patients harboring EGFR mutations.
    Li HS; Zhang JY; Yan X; Xu HY; Hao XZ; Xing PY; Wang Y
    Cancer Med; 2022 Feb; 11(4):1026-1036. PubMed ID: 35023313
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Next-generation sequencing reveals novel resistance mechanisms and molecular heterogeneity in EGFR-mutant non-small cell lung cancer with acquired resistance to EGFR-TKIs.
    Lee CK; Kim S; Lee JS; Lee JE; Kim SM; Yang IS; Kim HR; Lee JH; Kim S; Cho BC
    Lung Cancer; 2017 Nov; 113():106-114. PubMed ID: 29110836
    [TBL] [Abstract][Full Text] [Related]  

  • 26. An unbiased
    Chakroborty D; Kurppa KJ; Paatero I; Ojala VK; Koivu M; Tamirat MZ; Koivunen JP; Jänne PA; Johnson MS; Elo LL; Elenius K
    J Biol Chem; 2019 Jun; 294(24):9377-9389. PubMed ID: 30952700
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical outcomes and secondary epidermal growth factor receptor (EGFR) T790M mutation among first-line gefitinib, erlotinib and afatinib-treated non-small cell lung cancer patients with activating EGFR mutations.
    Lin YT; Chen JS; Liao WY; Ho CC; Hsu CL; Yang CY; Chen KY; Lee JH; Lin ZZ; Shih JY; Yang JC; Yu CJ
    Int J Cancer; 2019 Jun; 144(11):2887-2896. PubMed ID: 30485437
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Dual targeting of EGFR can overcome a major drug resistance mutation in mouse models of EGFR mutant lung cancer.
    Regales L; Gong Y; Shen R; de Stanchina E; Vivanco I; Goel A; Koutcher JA; Spassova M; Ouerfelli O; Mellinghoff IK; Zakowski MF; Politi KA; Pao W
    J Clin Invest; 2009 Oct; 119(10):3000-10. PubMed ID: 19759520
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Therapeutic strategy for advanced EGFR mutant non-small-cell lung carcinoma.
    Cadranel J; Ruppert AM; Beau-Faller M; Wislez M
    Crit Rev Oncol Hematol; 2013 Dec; 88(3):477-93. PubMed ID: 23911281
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Targeted sequencing identifies genetic alterations that confer primary resistance to EGFR tyrosine kinase inhibitor (Korean Lung Cancer Consortium).
    Lim SM; Kim HR; Cho EK; Min YJ; Ahn JS; Ahn MJ; Park K; Cho BC; Lee JH; Jeong HC; Kim EK; Kim JH
    Oncotarget; 2016 Jun; 7(24):36311-36320. PubMed ID: 27121209
    [TBL] [Abstract][Full Text] [Related]  

  • 31. EGFR Kinase Domain Duplication (EGFR-KDD) Is a Novel Oncogenic Driver in Lung Cancer That Is Clinically Responsive to Afatinib.
    Gallant JN; Sheehan JH; Shaver TM; Bailey M; Lipson D; Chandramohan R; Red Brewer M; York SJ; Kris MG; Pietenpol JA; Ladanyi M; Miller VA; Ali SM; Meiler J; Lovly CM
    Cancer Discov; 2015 Nov; 5(11):1155-63. PubMed ID: 26286086
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Acquired EGFR L718V mutation mediates resistance to osimertinib in non-small cell lung cancer but retains sensitivity to afatinib.
    Liu Y; Li Y; Ou Q; Wu X; Wang X; Shao YW; Ying J
    Lung Cancer; 2018 Apr; 118():1-5. PubMed ID: 29571986
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Not all epidermal growth factor receptor mutations in lung cancer are created equal: Perspectives for individualized treatment strategy.
    Kobayashi Y; Mitsudomi T
    Cancer Sci; 2016 Sep; 107(9):1179-86. PubMed ID: 27323238
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Rare mutations of epidermal growth factor receptor in epidermal growth factor receptor-tyrosine kinase inhibitor-naive non-small cell lung carcinoma and the response to erlotinib therapy.
    Sari M; Aydiner A
    J Cancer Res Ther; 2020; 16(1):132-138. PubMed ID: 32362623
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Acquired resistance to epidermal growth factor receptor kinase inhibitors associated with a novel T854A mutation in a patient with EGFR-mutant lung adenocarcinoma.
    Bean J; Riely GJ; Balak M; Marks JL; Ladanyi M; Miller VA; Pao W
    Clin Cancer Res; 2008 Nov; 14(22):7519-25. PubMed ID: 19010870
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Survival benefits from afatinib compared with gefitinib and erlotinib among patients with common EGFR mutation in first-line setting.
    Kwok WC; Ho JCM; Tam TCC; Ip MSM; Lam DCL
    Thorac Cancer; 2022 Jul; 13(14):2057-2063. PubMed ID: 35668712
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Overall signature of acquired KRAS gene changes in advanced non-small cell lung cancer patient with EGFR-TKI resistance.
    Zheng J; Dou Y; Huang D; Wang Y; Han R; Hu C; Zhu M; Lu C; Lin C; Wu D; Liu Y; Tang H; He T; Jiang W; He Y
    Jpn J Clin Oncol; 2024 Jan; 54(1):89-96. PubMed ID: 37721193
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Characterization of EGFR T790M, L792F, and C797S Mutations as Mechanisms of Acquired Resistance to Afatinib in Lung Cancer.
    Kobayashi Y; Azuma K; Nagai H; Kim YH; Togashi Y; Sesumi Y; Chiba M; Shimoji M; Sato K; Tomizawa K; Takemoto T; Nishio K; Mitsudomi T
    Mol Cancer Ther; 2017 Feb; 16(2):357-364. PubMed ID: 27913578
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Afatinib as First-Line Treatment in Asian Patients with EGFR Mutation-Positive NSCLC: A Narrative Review of Real-World Evidence.
    Lu S; Shih JY; Jang TW; Liam CK; Yu Y
    Adv Ther; 2021 May; 38(5):2038-2053. PubMed ID: 33730350
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The HSP90 inhibitor ganetespib potentiates the antitumor activity of EGFR tyrosine kinase inhibition in mutant and wild-type non-small cell lung cancer.
    Smith DL; Acquaviva J; Sequeira M; Jimenez JP; Zhang C; Sang J; Bates RC; Proia DA
    Target Oncol; 2015 Jun; 10(2):235-45. PubMed ID: 25077897
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.